Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.58 |
| ▸ | DRD2 | P14416 | 11/20 | 0.58 |
| ▸ | DRD3 | P35462 | 11/20 | 0.58 |
| ▸ | MMP3 | P08254 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12460742 | 0.98 | DRD4 (0.56) | DRD4DRD2DRD3MMP3HRH3 | |
| SCHEMBL1714981 | 0.94 | HRH3 (0.54) | DRD4DRD2DRD3MMP3HRH3 | |
| SCHEMBL1715002 | 0.94 | MMP3 (0.55) | DRD4DRD2DRD3MMP3HRH3 | |
| SCHEMBL12461737 | 0.91 | DRD4 (0.50) | DRD4DRD2DRD3MMP3HRH3 | |
| SCHEMBL8053774 | 0.91 | DRD4 (0.73) | DRD4DRD2DRD3 | |
| SCHEMBL9645057 | 0.91 | MMP3 (0.51) | DRD4DRD2DRD3MMP3HRH3 | |
| SCHEMBL16964732 | 0.89 | DRD4 (0.51) | DRD4DRD2DRD3MMP3HRH3 | |
| SCHEMBL12461513 | 0.88 | SCN8A (0.64) | DRD4DRD2DRD3MMP3SCN8A | |
| Hydrochloric Acid SCHEMBL5007304 | 0.88 | DRD4 (0.50) | DRD4DRD2DRD3MMP3HRH3 | |
| SCHEMBL4500549 | 0.85 | SMN1; SMN2 (0.54) | DRD4DRD2DRD3MMP3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | DRD4 1102/4885DRD2 1292/4885DRD3 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.